CTC at European Haematology Association conference 2018
13 September 2018
Amy Kirkwood, senior statistician at the Cancer Research UK and UCL Cancer Trials Centre, reports back from this year's edition of the EHA conference:

The CTC had excellent representation at EHA 23 in Stockholm this year, with eight abstracts from four trials presented (listed below). 

It was a bumper year for UKALL14, the UK’s front line study for adults with acute lymphoblastic leukaemia, which had two talks and three posters accepted for presentation. Four used data generated by translational projects from trial and the fifth focused on the outcomes of transplanted patients post-relapse. 

Quality of life analyses were presented for the Watch and Wait study, a trial looking at Rituximab vs watchful waiting in newly diagnosed Follicular lymphoma patients. 

A poster presented chemotherapy-related toxicity rates in overweight patients treated on the RATHL trial; overweight patients were not dose capped on this trial, but this did not cause them to experience an excessive amount of toxicity. 

Finally, the CTC’s haematology clinical fellow Dr Beth Phillips (pictured) discussed the results of the R-CODOX-M/IVAC trial for high-risk Diffuse Large B-cell lymphoma and Burkitt’s lymphoma, as well as presenting outcomes for high-risk subtypes. 


E. Phillips, et al. 
Favourable outcomes with R-CODOX-M/R-IVAC across all subgroups of aggressive high grade B-cell lymphoma: pathology and updated survival results from a phase 2 NCRI/LLR trial

UKALL14 orals

R. Burt, et al. 
Mesenchymal stromal cells protect acute lymphoblastic leukaemia cells from cytarabine induced apoptosis by transfer of mitochondria via tunnelling nanotubes in a treatment resistant niche model

A. Moorman, et al. 
Comprehensive screening of B-other adult ALL patients treated on UKALL14 estimates frequency and prognostic impact of gene alterations and identifies JAK-STAT abnormalities as markers of poor outcome

UKALL14 posters

R. Mitchell, et al. 
Prognostic value of IKZF1 deletions on the UKALL14 trial: significant role of BCR-ABL1 status

A. Castleton, et al. 
Characteristics and outcomes of adults with acute lymphoblastic leukaemia relapsing post-allogeneic haematopoietic cell transplantation in the prospective UKALL14 trial

K. Bailey, et al. 
Re-thinking the prognostic relevance of a CD20 expression cut off of 20% in acute lymphoblastic leukaemia: initial results from the UKALL14 trial

RATHL poster

B. Merron, et al. 
Overweight lymphoma patients treated by actual body weight had no excess of chemotherapy toxicity: experience from two large trials

Watch & Wait poster

M. Marzolini, et al. 
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting: phase 3 randomised international study

Photo: Beth Phillips presenting at the conference, by Amy Kirkwood

Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road

View map
+44 (0)20 7679 9898 (General CTC Enquiries)
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2022 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us